Luciana Teofili

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5848255/publications.pdf

Version: 2024-02-01

167	3,216	147801	189892
papers	citations	31 h-index	50 g-index

170	170	170	3542
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Transfusion-Free Survival Predicts Severe Retinopathy in Preterm Neonates. Frontiers in Pediatrics, 2022, 10, 814194.	1.9	12
2	Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. Bone Marrow Transplantation, 2022, 57, 837-839.	2.4	4
3	High Arterial Lactate Levels after Hepatic Resection Are Associated with Low Oxygen Delivery and Predict Severe Postoperative Complications. Biomedicines, 2022, 10, 1108.	3.2	0
4	Thromboelastography does not reduce transfusion requirements in liver transplantation: A propensity score-matched study. Journal of Clinical Anesthesia, 2021, 69, 110154.	1.6	10
5	Proposal of a new evidence based definition of Early Allograft Failure to identify patients who needs early retransplant and call for a prospective external validation study. Digestive and Liver Disease, 2021, 53, S44.	0.9	0
6	Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal. Cytotherapy, 2021, 23, 635-640.	0.7	14
7	ABO Mismatch in Allogeneic Hematopoietic Stem Cell Transplant: Effect on Short- and Long-term Outcomes. Transplantation Direct, 2021, 7, e724.	1.6	2
8	Letter to the Editor in response to: Fetal hemoglobin levels in premature newborns. Journal of Pediatric Surgery, 2021, 56, 2407-2408.	1.6	0
9	Human Amniotic Mesenchymal Stromal Cells Support the ex Vivo Expansion of Cord Blood Hematopoietic Stem Cells. Stem Cells Translational Medicine, 2021, 10, 1516-1529.	3.3	5
10	Protective effect of SARSâ€CoVâ€2 preventive measures against ESKAPE and Escherichia coli infections. European Journal of Clinical Investigation, 2021, 51, e13687.	3.4	18
11	Allogeneic cord blood red blood cells: assessing cord blood unit fractionation and validation. Blood Transfusion, 2021, 19, 435-444.	0.4	1
12	Validation plan of bone marrow collection, processing and distribution using the failure mode and effect analysis methodology: a technical report. Cytotherapy, 2021, , 1397.	0.7	0
13	Duplex Doppler evidence of high hepatic artery resistive index after liver transplantation: Role of portal hypertension and clinical impact. Digestive and Liver Disease, 2020, 52, 301-307.	0.9	8
14	Umbilical cord blood: Current uses for transfusion and regenerative medicine. Transfusion and Apheresis Science, 2020, 59, 102952.	1.0	16
15	â€œEarly transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trialâ€• Trials, 2020, 21, 875.	1.6	6
16	Infectious complications in neonatal transfusion: Narrative review and personal contribution. Transfusion and Apheresis Science, 2020, 59, 102951.	1.0	3
17	Pre-Exposure to Defibrotide Prevents Endothelial Cell Activation by Lipopolysaccharide: An Ingenuity Pathway Analysis. Frontiers in Immunology, 2020, 11, 585519.	4.8	7
18	Development and Validation of a Comprehensive Model to Estimate Early Allograft Failure Among Patients Requiring Early Liver Retransplant. JAMA Surgery, 2020, 155, e204095.	4.3	67

#	Article	IF	Citations
19	Allogeneic cord blood transfusions prevent fetal haemoglobin depletion in preterm neonates. Results of the CBâ€TrIP study. British Journal of Haematology, 2020, 191, 263-268.	2.5	21
20	Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes?. Cytotherapy, 2020, 22, 158-165.	0.7	10
21	Peyronie's disease in patients with Hodgkin lymphoma. Leukemia Research, 2020, 96, 106427.	0.8	1
22	Preoperative autologous blood donation in adult bone marrow donors: reappraisal of a singleâ€centre experience. Vox Sanguinis, 2019, 114, 762-768.	1.5	4
23	Rotating-disc micro-solid phase extraction of F2-isoprostanes from maternal and cord plasma by using oxidized buckypaper as sorbent membrane. Journal of Chromatography A, 2019, 1586, 30-39.	3.7	10
24	Postoperative respiratory failure in liver transplantation: Risk factors and effect on prognosis. PLoS ONE, 2019, 14, e0211678.	2.5	24
25	CORD BLOOD PLATELET LYSATE: IN VITRO EVALUATION TO SUPPORT THE USE IN REGENERATIVE MEDICINE.. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019021.	1.3	10
26	Unrelated cord blood transplantation and post-transplant cyclophosphamide. Haematologica, 2019, 104, e77-e78.	3.5	10
27	Indications and use of therapeutic phlebotomy in polycythemia vera: which role for erythrocytapheresis?. Leukemia, 2019, 33, 279-281.	7.2	10
28	Full Donor Chimerism after Allografts for Myelofibrosis: The Role of Conditioning Regimen. Blood, 2019, 134, 4490-4490.	1.4	0
29	Unrelated Cord Blood Transplantation and Post-Transplant Cyclophosphamide (PT-CY). Blood, 2019, 134, 3332-3332.	1.4	0
30	Foetal haemoglobin, blood transfusion, and retinopathy of prematurity. Eye, 2018, 32, 1155-1156.	2.1	5
31	SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders. Expert Review of Hematology, 2018, 11, 155-168.	2.2	4
32	Hierarchical Model to Predict Length of Stay and ICU Outcome According to Post-Operative Respiratory Failure after Liver Transplantation. Transplantation, 2018, 102, S446-S447.	1.0	0
33	Umbilical cord blood as a source for redâ€bloodâ€cell transfusion in neonatology: a systematic review. Vox Sanguinis, 2018, 113, 713-725.	1.5	25
34	Incorporating placental tissue in cord blood banking for stem cell transplantation. Expert Review of Hematology, 2018, 11, 649-661.	2.2	5
35	Red Cell Alloantibody Screening: Comparative Analysis of Three Different Technologies. Transfusion Medicine and Hemotherapy, 2018, 45, 179-183.	1.6	7
36	RNA editing signature during myeloid leukemia cell differentiation. Leukemia, 2017, 31, 2824-2832.	7.2	29

#	Article	IF	Citations
37	Platelet indices and glucose control in type 1 and type 2 diabetes mellitus: A case-control study. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 902-909.	2.6	22
38	Granulocyte Transfusions: A Critical Reappraisal. Biology of Blood and Marrow Transplantation, 2017, 23, 2034-2041.	2.0	20
39	Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. PLoS ONE, 2017, 12, e0186549.	2.5	29
40	Graft Composition and Post-Thawing Cell Viability Influence the Hematopoietic Recovery in Autologous Hematopoietic Stem Cell Transplantation. Journal of Stem Cell Research & Therapy, 2017, 07, .	0.3	2
41	Effects of exposure to gradient magnetic fields emitted by nuclear magnetic resonance devices on clonogenic potential and proliferation of human hematopoietic stem cells. Bioelectromagnetics, 2016, 37, 201-211.	1.6	10
42	Cytokine profile of autologous plateletâ€derived eye drops in patients with ocular chronic graftâ€versusâ€host disease. Vox Sanguinis, 2016, 110, 189-192.	1.5	9
43	The combined effect of subcutaneous granulocyte- colony stimulating factor and myocardial contrast echocardiography with intravenous infusion of sulfur hexafluoride on post-infarction left ventricular function, the RIGENERA 2.0 trial: study protocol for a randomized controlled trial. Trials, 2016, 17, 97.	1.6	6
44	Human cord blood endothelial progenitors promote post-ischemic angiogenesis in immunocompetent mouse model. Thrombosis Research, 2016, 141, 106-111.	1.7	34
45	Dose-Dependent Effect of Granulocyte Transfusions in Hematological Patients with Febrile Neutropenia. PLoS ONE, 2016, 11, e0159569.	2.5	21
46	Weak D Type 4.2.2 (DAR1.2) in an African child: Serology and molecular characterization. Transfusion and Apheresis Science, 2015, 52, 217-219.	1.0	0
47	Endothelial Progenitor Cell Dysfunction in Myelodysplastic Syndromes: Possible Contribution of a Defective Vascular Niche to Myelodysplasia. Neoplasia, 2015, 17, 401-409.	5.3	24
48	InÂvitro cardiomyocyte differentiation of umbilical cord blood cells: crucial role for c-kit+ cells. Cytotherapy, 2015, 17, 1627-1637.	0.7	7
49	An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome. Blood Cancer Journal, 2015, 5, e370-e370.	6.2	0
50	Allogeneic Umbilical Cord Blood Red Cell Concentrates: An Innovative Blood Product for Transfusion Therapy of Preterm Infants. Neonatology, 2015, 107, 81-86.	2.0	36
51	Granulocyte Transfusions at Appropriate Doses Improve Survival in Hematological Patients with Febrile Neutropenia. Blood, 2015, 126, 3566-3566.	1.4	0
52	ACUTE LUNG INJURY COMPLICATING BLOOD TRANSFUSION IN POST-PARTUM HEMORRHAGE: INCIDENCE AND RISK FACTORS.. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014069.	1.3	22
53	Medicine use in pregnancy and public cord blood bank databases. Pharmacoepidemiology and Drug Safety, 2014, 23, 1107-1109.	1.9	1
54	Primary myelofibrosis: when the clone manifests with Rh phenotype splitting. Annals of Hematology, 2014, 93, 1077-1078.	1.8	3

#	Article	IF	Citations
55	CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence. Blood, 2014, 123, 3677-3679.	1.4	22
56	Adult and cord blood endothelial progenitor cells have different gene expression profiles and immunogenic potential. Blood Transfusion, 2014, 12 Suppl 1, s367-74.	0.4	17
57	Primary Trombocythemia in Children and Adolescents Includes Different Subtypes Compared to Adult Essential Thrombocythemia. Blood, 2014, 124, 1865-1865.	1.4	0
58	Abnormal Mirna Expression Profile and Cytokine Production in Myelodysplastic Vascular Niche. Blood, 2014, 124, 1890-1890.	1.4	0
59	Use of allogenic umbilical cord blood for red cells transfusion in premature infants: utopia or reality?. Early Human Development, 2013, 89, S49-S51.	1.8	18
60	P-236 Endothelial progenitor cells in MDS patients show specific genetic signatures and abnormal cytokine production which could contribute to myelodysplastic hematopoiesis. Leukemia Research, 2013, 37, S129-S130.	0.8	0
61	Blood and endothelial cells: together through thick and thin. Blood, 2013, 121, 248-249.	1.4	3
62	Effect of antiviral therapy on pro-angiogenic hematopoietic and endothelial progenitor cells in HIV-infected people. Thrombosis Research, 2013, 131, 238-243.	1.7	17
63	Endothelial Progenitor Cells in HIV-Positive Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, e22-e23.	2.1	2
64	Mantle cell lymphoma relapsing at the lymphedematous arm.. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013016.	1.3	2
65	Short Communication: Proangiogenic Hematopoietic Cells In Acute HIV Infection. AIDS Research and Human Retroviruses, 2013, 29, 307-310.	1.1	5
66	Pregnancy-Related Hypertensive Disorders Are The Major Risk Factor For TRALI In Patients With Severe Post-Partum Hemorrhage. Blood, 2013, 122, 1159-1159.	1.4	3
67	Hypoxia-inducible factor-1Î±(Pro-582-Ser) polymorphism prevents iron deprivation in healthy blood donors. Blood Transfusion, 2013, 11, 553-7.	0.4	10
68	Transfusion Of Very Low Birth Weight Neonates Using Allogeneic Cord Blood Derived RBC Units. Blood, 2013, 122, 2398-2398.	1.4	0
69	Defective WNT Signaling and Genetic Profile Of Endothelial Cells In Patients With Low Risk Myelodysplastic Syndromes Suggest a Contribution Of Vascular Niches To Myelodysplasia. Blood, 2013, 122, 860-860.	1.4	0
70	Primary Pancreatic Lymphoma in a Patient with Maturity Onset Diabetes of the Young type 3. Mediterranean Journal of Hematology and Infectious Diseases, 2012, 4, e2012005.	1.3	2
71	Epstein-Barr Virus (EBV)-associated Haemophagocytic Syndrome. Mediterranean Journal of Hematology and Infectious Diseases, 2012, 4, e2012008.	1.3	6
72	von Hippel-Lindau Disease and Erythrocytosis. Journal of Clinical Oncology, 2012, 30, e137-e139.	1.6	16

#	Article	IF	Citations
73	Does â€œmoreâ€•necessarily mean â€œbetterâ€?. Blood, 2012, 119, 3194-3196.	1.4	0
74	Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood, 2012, 119, 2219-2227.	1.4	78
75	Endothelial progenitor cells and thrombosis. Thrombosis Research, 2012, 129, 309-313.	1.7	9
76	Transfuse Neonates with Cord Blood-Derived Red Blood Cells: A Feasibility Study to Assess Allogeneic Cord Blood Unit Fractionation and Validation. Blood, 2012, 120, 275-275.	1.4	11
77	The Contact with MDS Endothelial Cells Alters the Pattern of Lineage-Specific Gene Expression During Normal Hematopoietic Differentiation. Blood, 2012, 120, 1718-1718.	1.4	0
78	Endothelial progenitor cells are clonal and exhibit the JAK2V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood, 2011, 117, 2700-2707.	1.4	111
79	Response to 5â€•azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapyâ€•related myelodysplastic syndrome. British Journal of Haematology, 2011, 154, 141-143.	2.5	6
80	Advances in understanding the pathogenesis of familial thrombocythaemia. British Journal of Haematology, 2011, 152, 701-712.	2.5	37
81	Cauda equina enhancing lesion in a HIV-positive patient. Case report and literature revision.. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011042.	1.3	2
82	115 poster: Prognostic Value of Pre-Radiotherapy FDG-PET in Advanced Hodgkinâ€™S Disease Treated by Beacopp Chemotherapy Regimen. Radiotherapy and Oncology, 2010, 94, S44-S45.	0.6	0
83	Endothelial progenitor cell trafficking in human immunodeficiency virus-infected persons. Aids, 2010, 24, 2443-2450.	2.2	33
84	Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica, 2010, 95, 65-70.	3.5	79
85	Essential thrombocythemia as underlying cause of malabsorption syndrome. Annals of Hematology, 2010, 89, 1067-1068.	1.8	0
86	Detrimental clinical interaction between ritonavirâ€•boosted protease inhibitors and vinblastin in HIVâ€•infected patients with Hodgkin lymphoma. Journal of the International AIDS Society, 2010, 13, P215.	3.0	1
87	Thrombopoietin Receptor Activation, Thrombopoietin Mimetic Drugs, and Hereditary Thrombocytosis: Remarks on Bone Marrow Fibrosis. Journal of Clinical Oncology, 2010, 28, e317-e318.	1.6	9
88	Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma. Aids, 2010, 24, 2408-2412.	2.2	27
89	Primary cerebral lymphomatoid granulomatosis: report of four cases and literature review. Journal of Neuro-Oncology, 2009, 94, 235-242.	2.9	66
90	The mutant JAK2^{V617F} allele burden in children with essential thrombocythemia. British Journal of Haematology, 2009, 145, 430-432.	2.5	10

#	Article	IF	Citations
91	Intravascular large B cell lymphoma: when lymphoma is suspected but routine diagnostic work-up is negative. Leukemia and Lymphoma, 2009, 50, 1900-1903.	1.3	4
92	Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica, 2009, 94, 1368-1374.	3.5	53
93	COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009020.	1.3	2
94	Clinical and Biological Features, Treatment and Long-Term Outcome of 65 Children with Ph- Myeloprolipherative Disorders (MPD).. Blood, 2009, 114, 1889-1889.	1.4	0
95	Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. International Journal of Cancer, 2008, 123, 1586-1592.	5.1	50
96	Phosphorylated STAT5 Represents a New Possible Prognostic Marker in Hodgkin Lymphoma. American Journal of Clinical Pathology, 2008, 129, 472-477.	0.7	18
97	Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?. Haematologica, 2008, 93, 169-172.	3.5	29
98	A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. Haematologica, 2008, 93, 1068-1071.	3.5	64
99	Retrospective Evaluation of 90 Children with Essential Thrombocytemia: The AIEOP Experience. Blood, 2008, 112, 664-664.	1.4	3
100	Hereditary Thrombocythemia: Clinical Characteristics, Biological Markers and Long-Term Follow-up in 4 Families Observed in a Single Hematologic Pediatric Center. Blood, 2008, 112, 5226-5226.	1.4	0
101	Markers of Myeloproliferative Diseases in Childhood Polycythemia Vera and Essential Thrombocythemia. Journal of Clinical Oncology, 2007, 25, 1048-1053.	1.6	107
102	Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood, 2007, 110, 354-359.	1.4	71
103	The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood, 2007, 110, 3384-3386.	1.4	50
104	Blastoid Mantle Cell Lymphoma Occurring in a Patient in Complete Remission of Chronic Myelogenous Leukemia. Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology, 2007, 13, 30-33.	1.2	3
105	Overexpression of <I>PRV-1</I> Gene in Polycythemia Rubra Vera and Essential Thrombocythemia. , 2006, 125, 265-274.		5
106	Clonality Assay (X-CIP) and JAK 2 V617P Mutation: Clustering Patients with Essential Thrombocythemia at High Risk for Thrombosis.. Blood, 2005, 106, 2597-2597.	1.4	1
107	Combined Muliparameter Approach to the Diagnosis of Polycythemia Vera and Essential Thrombocythemia.. Blood, 2005, 106, 4950-4950.	1.4	0
108	The PRV-1 gene expression in essential thrombocythemia. Blood, 2004, 104, 2995-2996.	1.4	7

#	Article	IF	Citations
109	Hypermethylation of GpG islands in the promoter region of p15INK4b in acute promyelocytic leukemia represses p15INK4b expression and correlates with poor prognosis. Leukemia, 2003, 17, 919-924.	7.2	55
110	Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clinical Immunology, 2003, 109, 89-102.	3.2	93
111	Overexpression of the Polycythemia Rubra Vera-1 Gene in Essential Thrombocythemia. Journal of Clinical Oncology, 2002, 20, 4249-4254.	1.6	51
112	The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia. Blood, 2002, 100, 714-717.	1.4	40
113	DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica, 2002, 87, 1324-41.	3.5	123
114	Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood, 2001, 97, 1063-1069.	1.4	74
115	Acquired and inherited risk factors for splanchnic venous thrombosis. Blood, 2001, 97, 3314-3316.	1.4	2
116	Expression of p15ink4b gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. Blood, 2001, 98, 495-497.	1.4	42
117	Blood cells diseases and thrombosis. Haematologica, 2001, 86, 1236-44.	3.5	29
118	MiCMA: An alternative treatment for refractory or recurrent Hodgkin's disease. Annals of Oncology, 2000, 11, 867-871.	1.2	8
119	Short term treatment withEscheria coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease. , 2000, 88, 454-460.		12
120	Expression of cyclin-dependent kinase inhibitor p15INK4B during normal and leukemic myeloid differentiation. Experimental Hematology, 2000, 28, 519-526.	0.4	37
121	Lymphoid blastic crisis in Philadelphia chromosome-positive chronic granulocytic leukemia following high-grade non-Hodgkin's lymphoma A case report and review of literature. Haematologica, 2000, 85, 544-8.	3.5	9
122	Isolated primary Hodgkin's disease of rectum. Haematologica, 2000, 85, 986-7.	3.5	3
123	Cerebral Vein Thrombosis not Related to Use of Oral Contraceptives in a 7-year-old Child Carrier of the Prothrombin 20210A Allele. Thrombosis and Haemostasis, 1999, 81, 991-992.	3.4	2
124	Oral ipriflavone (7-isopropoxyisoflavone) treatment for elderly patients with resistant acute leukemias. Annals of Oncology, 1999, 10, 124-125.	1.2	11
125	Expression of p53, Bcl-2, and Bax in CD34+ Cells Recovering After Chemotherapy. Blood, 1998, 92, 4880-4881.	1.4	7
126	Hepatic Vein Thrombosis in a Patient with Mutant Prothrombin 20210A Allele. Thrombosis and Haemostasis, 1998, 80, 519-519.	3.4	11

#	Article	IF	Citations
127	Expression of p53, Bcl-2, and Bax in CD34+ Cells Recovering After Chemotherapy. Blood, 1998, 92, 4880-4881.	1.4	0
128	Hepatic vein thrombosis in a patient with mutant prothrombin 20210A allele. Thrombosis and Haemostasis, 1998, 80, 519.	3.4	1
129	Expression of p15INK4B in normal hematopoiesis. Experimental Hematology, 1998, 26, 1133-9.	0.4	25
130	Spontaneous Erythroid Colony Formation as the Clue to an Underlying Myeloproliferative Disorder in Patients with Budd-Chiari Syndrome or Portal Vein Thrombosis. Seminars in Thrombosis and Hemostasis, 1997, 23, 411-418.	2.7	169
131	Inhibition of lymphocyte blastogenic response in healthy donors treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF): possible role of lactoferrin and interleukin-1 receptor antagonist. Bone Marrow Transplantation, 1997, 20, 355-364.	2.4	26
132	Differential sensitivity of leukemic and normal hematopoietic progenitors to the killing effect of hyperthermia and quercetin used in combination: Role of heat-shock protein-70. , 1997, 73, 75-83.		32
133	RhG-CSF-mobilized CD34+ peripheral blood progenitors are myeloperoxidase-negative and noncycling irrespective of CD33 or CD13 coexpression. Experimental Hematology, 1997, 25, 246-51.	0.4	28
134	Hodgkin's lymphoma in a cyclist treated with growth hormone. , 1996, 52, 65-66.		12
135	Quercetin and the Growth of Leukemic Progenitors. Leukemia and Lymphoma, 1996, 23, 49-53.	1.3	20
136	RhG-CSF-mobilized peripheral blood haemopoietic progenitors reside in G0/G1 phase of cell cycle independently of the expression of myeloid antigens. British Journal of Haematology, 1996, 93, 737-8.	2.5	4
137	Separation of chemotherapy plus G-CSF-mobilized peripheral blood mononuclear cells by counterflow centrifugal elutriation: in vitro characterization of two different CD34+ cell populations. Bone Marrow Transplantation, 1996, 18, 421-5.	2.4	2
138	Effect of all-trans retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia. Blood, 1995, 86, 3535-3541.	1.4	55
139	Quercetin inhibits the growth of leukemic progenitors and induces the expression of transforming growth factor-beta 1 in these cells. Blood, 1995, 85, 3654-3661.	1.4	41
140	Sequential peripheral blood progenitor cell transplantation after mobilization with salvage chemotherapy and G-CSF in patients with resistant lymphoma. American Journal of Hematology, 1994, 46, 18-23.	4.1	12
141	Characterization of peripheral blood CD34+ progenitor cells mobilized with chemotherapy and granulocyte colony-stimulating factor. Experimental Hematology, 1994, 22, 990-5.	0.4	10
142	In vitro and in vivo effects of recombinant human erythropoietin plus recombinant human G-CSF on human haemopoietic progenitor cells. Bone Marrow Transplantation, 1994, 14, 23-30.	2.4	13
143	Further investigations on the expression of HLA-DR, CD33 and CD13 surface antigens in purified bone marrow and peripheral blood CD34Â± haematopoietic progenitor cells. British Journal of Haematology, 1993, 84, 24-30.	2.5	39
144	Haemopoietic CD34+ progenitor cells are not infected by HIV-1 in vivo but show impaired clonogenesis. British Journal of Haematology, 1993, 85, 20-24.	2.5	74

#	Article	IF	Citations
145	Effect of all-transretinoic acid on procoagulant activity of promyelocytic blast cells in culture. Thrombosis Research, 1993, 70, S55.	1.7	0
146	Evaluation of a Novel Automated Protocol for the Collection of Peripheral Blood Stem Cells Mobilized with Chemotherapy or Chemotherapy Plus G-CSF Using the Fresenius AS104 Cell Separator. Stem Cells and Development, 1993, 2, 145-153.	1.0	17
147	In Vitro Expansion of CD34+ Cells Mobilized with Chemotherapy and G-CSF. International Journal of Artificial Organs, 1993, 16, 89-95.	1.4	2
148	L-Asparaginase-Induced Coagulopathy in Acute Lymphoblastic Leukemia. Leukemia and Lymphoma, 1992, 7, 54-56.	1.3	2
149	The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growth. Leukemia Research, 1992, 16, 497-503.	0.8	49
150	Effects of a preformed extracellular matrix on long-term serum-free bone marrow culture. Annals of Hematology, 1992, 65, 22-25.	1.8	4
151	DISAPPEARANCE OF SPONTANEOUS ERYTHROID COLONIES IN PATIENTS WITH MYELOPROLIFERATIVE DISORDERS TREATED BY ALPHA-INTERFERON. British Journal of Haematology, 1992, 81, 310-311.	2.5	3
152	Acute onset of juvenile myelodysplastic syndrome mimicking thrombotic thrombocytopenic purpura and rapidly evolving in overt myeloid leukemia. American Journal of Hematology, 1992, 41, 64-65.	4.1	7
153	An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. Cancer, 1992, 70, 1647-1649.	4.1	0
154	Hematological Causes of Venous Thrombosis in Young People: High Incidence of Myeloproliferative Disorder as Underlying Disease in Patients with Splanchnic Venous Thrombosis. Thrombosis and Haemostasis, 1992, 67, 297-301.	3.4	43
155	Lymph node blast crisis in chronic myeloid leukemia mimicking T-immunoblastic lymphoma. Haematologica, 1992, 77, 311-4.	3.5	8
156	Hematological causes of venous thrombosis in young people: high incidence of myeloproliferative disorder as underlying disease in patients with splanchnic venous thrombosis. Thrombosis and Haemostasis, 1992, 67, 297-301.	3.4	4
157	Antiproliferative activity of quercetin on normal bone marrow and leukaemic progenitors. British Journal of Haematology, 1991, 79, 562-566.	2.5	51
158	Arterial thrombosis as clinical manifestation of congenital protein C deficiency. Annals of Hematology, 1991, 62, 180-183.	1.8	36
159	Ultrasound-Doppler Diagnosis of Budd-Chiari Syndrome. Journal of Clinical Gastroenterology, 1990, 12, 591-594.	2.2	3
160	Type II oestrogen binding sites in acute lymphoid and myeloid leukaemias: growth inhibitory effect of oestrogen and flavonoids. British Journal of Haematology, 1990, 75, 489-495.	2.5	83
161	Mesenteric vein thrombosis in protein S congenital deficiency. Thrombosis Research, 1990, 57, 935-944.	1.7	12
162	Association of Graves' disease and prekallikrein congenital deficiency in a patient belonging to the first CRM+ prekallikrein-deficient italian family. Thrombosis Research, 1990, 60, 397-404.	1.7	25

#	Article	IF	Citations
163	ASSOCIATION OF CONGENITAL PROTEIN C DEFICIENCY AND LATENT MYELOPROLIFERATIVE DISEASE AS CAUSE OF SPLANCHNIC VENOUS THROMBOSIS IN A 34â€YEARâ€OLD WOMAN. British Journal of Haematology, 1989, 73, 565-566.	2.5	4
164	Transient ischemic attack in a patient with congenital protein-c deficiency during treatment with stanozolol. American Journal of Hematology, 1988, 29, 120-121.	4.1	17
165	Antithrombin III Molecular Variants with Defective Binding to Heparin or to Serine Proteases: Evidence of Two Different Abnormal Patterns Identified by Crossed Immunoelectrofocusing. Thrombosis and Haemostasis, 1988, 60, 008-012.	3.4	4
166	Serum beta 2 microglobulin in psoriasis and psoriatic patients. Klinische Wochenschrift, 1987, 65, 341-341.	0.6	1
167	Cerebrospinal fluid betaâ€2â€microglobulin: A reliable index of leukaemic infiltration of central nervous system. European Journal of Haematology, 1986, 37, 301-305.	2.2	5